GRIA1 and schizophrenia: In order to evaluate the enhancement of GluA1-AMPAR function as a therapeutic concept in schizophrenia, it is vital to understand through which cell types and neural circuits GluA1 hypofunction may contribute to specific psychiatric deficits and to identify its broader contributions to cognition.